Sales Manager

Model N Appoints Bret Connor as CEO to Drive Next Phase of Growth. by Healthcare Executive Hires 01/06/2025 Leave a Comment. Bret Connor, CEO at Model NWhat You Should Know: – Model N, a leading provider of revenue optimization and compliance solutions for life sciences and high-tech companies, announced the appointment of Bret Connor as Chief Executive Officer. – Connor brings a wealth of experience in driving customer success and operational excellence, positioning Model N for continued growth and market leadership.  Bret Connor Bio/BackgroundConnor joins Model N from athenahealth, where he served as Chief Operating Officer. During his tenure, he played a key role in the company’s transition to private ownership and spearheaded initiatives focused on client satisfaction and operational excellence. Under his leadership, athenahealth achieved record-high Net Promoter Scores and client retention rates, culminating in a successful recapitalization for $17 billion in 2022. He previously held executive roles at VMware, leading their Professional Services business in the Americas

Latest innovations leverage GenAI and enriched data to strengthen global expansion, compliance, and channel sales.SAN MATEO, Calif. – November 20, 2024 – Model N, the leader in revenue optimization and compliance for life sciences and high-tech companies, launched new generative AI (GenAI) and expanded data capabilities to strengthen its core product suite. Integrating GenAI and intelligent data into the company’s Channel Data Management, Formulary Compliance, and Provider Management solutions showcases Model N's strong commitment to delivering continuous innovation and excellence to the world’s most innovative brands in life sciences and high tech.“The opportunity to harness the power of GenAI and intelligent data to help our customers drive revenue growth, strengthen compliance, and achieve market success couldn’t be greater. As we look ahead, continuing to innovate with AI technologies in our product portfolio remains a top priority – empowering our customers to deliver life-changing products,” said Suresh Kannan, Chief Product Officer, Model N.Bolstering Channel Sales by Leveraging GenAIModel N’s new generative AI Catalog Discovery is a part of its Channel Data Management solution that effectively helps high tech companies manage revenue from indirect sources. GenAI Catalog Discovery automates point-of-sale (POS) data processing, converting unstructured product descriptions into structured, actionable data, regardless of language. High-tech manufacturers can use the AI output to identify how their products are used and bundled for consumption

Model N Introduces New Rebate Enhancement, as Pharma Companies Prepare for Impact from the Inflation Reduction ActNew Medicare Part D inflation rebate enhancement helps pharma manufacturers manage pricing reformsModel N (NYSE: MODN), the leader in revenue optimization and compliance has introduced a critical product enhancement that supports evolving compliance needs around the Inflation Reduction Act (IRA). The company has introduced a new Medicare Part D inflation rebate-per-unit, ensuring pharma manufacturers remain compliant with impending IRA regulation and avoid significant revenue loss."The Inflation Reduction Act introduces sweeping changes for drug pricing and Medicare programs, and our goal is to empower customers to stay ahead of these shifts," said Suresh Kannan, Chief Product Officer at Model N. "As our life sciences customers prepare for new reforms and regulatory changes, Model N's latest product innovations address a critical market need by providing the capabilities necessary to calculate and process complex Medicare Part D inflation rebates.”According to Model N’s 2024 State of Revenue Report, pharmaceutical executives are preparing for a significant revenue impact from the IRA. The law aims to lower prescription drug costs for Medicare beneficiaries through provisions allowing the program to negotiate prices for certain high-cost drugs and requiring manufacturers to pay rebates for any price changes higher than the inflation rate. Effective for Medicare Part B and D drugs, manufacturers must calculate inflation penalties based on pricing increases over the designated benchmark periods.Model N's new inflation rebate feature empowers customers to calculate Medicare Part D inflation rebate-per-unit, ensuring compliance with the upcoming IRA regulation set to take effect in 2025. Coupled with Model N's Government Pricing, Payer Management, Provider Management, and Validata solutions, customers gain a unified, end-to-end process to manage pricing strategy, calculate fees, and issue rebate payments in compliance with IRA guidance.The company is committed to ensuring that pharma customers are equipped with the most up-to-date technology to comply with IRA guidance, which will continue to evolve into 2026